We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · March 29, 2021

Off-Label AREDS 2 Supplementation

Clinical Ophthalmology (Auckland, N.Z.)


Additional Info

Clinical Ophthalmology (Auckland, N.Z.)
Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiecta
Clin Ophthalmol 2021 Mar 01;15(15)1133-1143, TA Berger, MW Manry, LB Lindsell, JM Osher, DM Miller, RE Foster, CD Riemann, MR Petersen, RA Sisk

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading